Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xencor, Inc.
ViroMissile, Inc.
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Baylor College of Medicine
Novartis
University Health Network, Toronto
AstraZeneca
IDEAYA Biosciences
Chongqing Precision Biotech Co., Ltd
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Incyte Corporation
Novita Pharmaceuticals, Inc.
Trishula Therapeutics, Inc.
Monopar Therapeutics
Monopar Therapeutics
Thomas Jefferson University
Columbia University
University of California, Davis
Revolution Medicines, Inc.
Checkpoint Therapeutics, Inc.
Inhibrx Biosciences, Inc
Keythera (Suzhou) Pharmaceuticals Co. Ltd
Celldex Therapeutics
University of California, San Francisco
STCube, Inc.
AO GENERIUM
Corvus Pharmaceuticals, Inc.
Lebanese University
Fate Therapeutics
Canadian Cancer Trials Group
Cantargia AB
Viralytics
Bristol-Myers Squibb
Quadriga Biosciences, Inc.
Revolution Medicines, Inc.
Imperial College London
Syndax Pharmaceuticals
Pfizer
Incyte Corporation
Novartis
Shionogi Inc.
Syndax Pharmaceuticals
BioNTech SE
National Institutes of Health Clinical Center (CC)